Overview
The registry aims to document epidemiologic data, treatment and long-term outcome as well as quality of life of patients with APL. Additionally, a biobanking project for further translational studies is integrated.
Prospective population-based non-interventional and non-randomized multicenter registry.
Description
- collection of epidemiological data for APL: age distribution, prognostic factors,
distribution of subgroups, incidence
- documentation of efficacy and safety of the first line and salvage therapy in APL including
- documentation of minimal residual disease (MRD)
- correlation of clinical outcomes with chosen therapy
- collection and evaluation of quality of life
- validation of published prognostic factors / new potential prognostic factors
- acquisition of bone marrow, peripheral blood and buccal swab samples for biobanking and translational studies under the umbrella of the specific study-group biobanking concepts
Eligibility
Inclusion Criteria:
- newly-diagnosed APL (either de novo or therapy-related), within 12 months of diagnosis
- or relapsed APL, within 12 months of diagnosis of relapse
- confirmed by the presence of the translocation t(15; 17)
- and / or confirmed by the detection of the fusion transcript of PML/RARa
Exclusion Criteria:
- none